Changes in triglyceride levels in ultra‐high risk for psychosis individuals treated with omega‐3 fatty acids. Issue 1 (11th September 2015)

• Record Type: Journal Article
• Authors: Mossaheb, Nilufar; Papageorgiou, Konstantinos; Schäfer, Miriam R.; Becker, Jana; Schloegelhofer, Monika; Amminger, G. Paul
• Is Part Of: Early intervention in psychiatry. Volume 12:Issue 1(2018:Feb.)
• Page Start: 30
• Page End: 36
• Publication Date: 2015-09-11
• Subjects: lipid -- omega‐3 fatty acid -- psychosis -- triglyceride -- ultra‐high risk; Mental health -- Periodicals; Psychiatry -- Periodicals; Psychiatry -- Research -- Periodicals; Mental illness -- Prevention -- Research -- Periodicals; Mental illness -- Treatment -- Research -- Periodicals; 616.89
• DOI: 10.1111/eip.12275
• Languages: English
• ISSNs: 1751-7885

Abstract

Abstract: Aim: The aim of this analysis was to assess changes in lipid parameters, specifically in triglyceride (TG) levels, in a population at ultra‐high risk (UHR) for psychosis treated with ω‐3 polyunsaturated fatty acids (PUFAs) versus placebo. Methods: Data were derived from a randomized, double‐blind, placebo‐controlled trial conducted at an early psychosis unit. Eighty‐one individuals, aged 13–25 years, at UHR for psychosis participated in a 12‐week intervention trial of 1.2 g/day of ω‐3 PUFAs ( n = 41) versus placebo ( n = 40). Lipid and C‐reactive protein levels were collected at baseline and after 12 weeks. Results: Between‐group comparisons showed no significant difference in TG levels after the intervention. However, in individuals with baseline TG levels above 150 mg dL −1 there was a significant mean TG reduction of 67.29 (SD 42.54; P = 0.006) in the ω‐3 group ( n = 7). Conclusion: In this sample of UHR individuals, a 12‐week intervention with ω‐3 PUFAs was effective in reducing previously elevated TG levels. This might introduce the possibility of altering the lipid profile and thus the risk of cardiovascular morbidity of UHR individuals.